Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

3q26 rearrangements (MECOM) in myeloid malignancies

Written2003-02Bruce Poppe, Nicole Dastugue, Frank Speleman
Centre for Medical Genetics, 1K5, University Hospital Ghent, De Pintelaan 185, 9000 Gent, Belgium

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS
ICD-Morpho 9861/3 AML with mutated NPM1; AML with mutated CEBPA; Acute myeloid leukaemia, NOS
ICD-Morpho 9975/3 Chronic myelogenous leukaemia, BCR-ABL1 positive; Myeloproliferative neoplasm, unclassifiable; Myelodysplastic/myeloproliferative neoplasm, unclassifiable
ICD-Morpho 9989/3 Myelodysplastic syndrome, unclassifiable
Atlas_Id 1125
 

Clinics and Pathology

Disease In myeloid malignancies (acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myelogenous leukemia (CML) as well as other myeloproliferative disorders), involvement of 3q26 in balanced rearrangements is highly suggestive of EVI1 and/or MDS1/EVI1 rearrangement. As a consequence, balanced aberrations involving 3q26 are mainly detected in myeloid malignancies.
Epidemiology 3q26 rearrangements have been described in up to 5% of unselected patients with myeloid malignancies.
Clinics Often associated with young age at diagnosis, trilineage dysplasia, dysmegakaryopoiesis and prior treatment with alkylating agents.
Evolution In CML, emergence of an additional Ph+ clone with a 3q26 rearrangement can be indicative of a pending disease transformation.
Prognosis Generally 3q26 rearrangements are associated with adverse prognosis. This adverse prognosis probably correlates to the highly increased EVI1 expression, detectable in the vast majority of these patients. Whether 3q26 rearrangements, which are not associated with ectopic EVI1 expression share the same prognostic features, however, has not been addressed.

Cytogenetics

Cytogenetics Morphological Although the frequently occurring balanced 3q26 rearrangements can be readily identified by G-, Q-, or R-banding, the distal localisation makes it a good candidate for involvement in cryptic aberrations. Rearrangements in which EVI1 and or MDS1/EVI1 involvement have been well established include: CYTOGENETICS_MORPHOL
  • t(3;3)(q21;q26)
  • inv(3)(q21q26)
  • ins(3)(q26;q21q26)
  • t(3;12)(q26;p13)
  • t(3;21)(q26;q22)

    Recently we demonstrated EVI1 involvement in other recurrent rearrangements such as :

  • t(2;3)(p13-p23;q26)
  • t(3;6)(q26;q25).
  • t(3;13)(q26;q14)
  • t(3;17)(q26;q22)

    In addition, EVI1 is involved in more rare rearrangements such as

  • inv(3)(p12q26)
  • inv(3)(q23q26)
  • t(3;3)(p24;q26)
  • t(3;5)(q26;q34)
  • t(3;9)(q26;p23)
  • t(3;12)(q26;q21)
  • t(3;18)(q26;q11).

    One should be aware of the fact, however, that in the majority of patients demonstrating ectopic EVI1 expression, 3q26 rearrangements are generally not detectable cytogenetically. Whether in these patients cryptic aberrations cause EVI1 deregulation is currently under investigation.

  • Cytogenetics Molecular Breakpoint heterogeneity, with breakpoints mapping 3¹ as well as 5¹, of EVI1 impeded a sensitive detection of EVI1 rearrangement using molecular cytogenetic techniques. Recently, however, we studied numerous 3q26 rearrangements using a 1.3Mb contig covering the EVI1 locus. We demonstrated sensitive and specific detection of EVI1 rearrangements using dual colour FISH using the following probe combinations: RP11-82C9 and RP11-694D5 for 5¹ rearrangements and RP11-82C9 and RP11-362K14 for 3¹ rearrangements.
    Additional anomalies 3q26 rearrangements are frequently associated with monosomy 7 and complex chromosomal aberrations.

    Genes involved and Proteins

    Gene Name MECOM
    Location 3q26.2
    Note EVI1 and MDS1 display intergenic splicing, creating a PR domain member, MDS1/EVI1. Analogously to other PR domain genes, such as RIZ, MDS1/EVI1 and EVI1 are hypothesised to display antagonistic properties. Currently, experimental data are limited and conflicting indicating that further experiments are needed to clarify the exact role of both evolutionary conserved transcripts.
      The different transcripts encoded by the EVI1 locus.
    Dna / Rna EVI1 spans approximately 50 kb and contains 12 exons, 10 of which are coding. Translation starts in exon 3.
    MDS1/EVI1 results from intergenic splicing from MDS1 and EVI1, the resulting transcript MDS1/EVI1, contains the 2 first MDS1 exons spliced in frame to EVI1 exon 2.
    The MDS1 gene spans approximately 230kb.
    Protein The EVI1 gene encodes a sequence specific Cys2/Hys2 type 145kDa zinc finger protein, containing two sets of seven and three zing fingers, respectively. Alternative splicing creates a 88 kDa isoform that lacks the nuclear localisation signal and two zinc fingers. MDS1/EVI1 encodes a PR domain family member. The PR domain is suggested to play an inhibiting role in tumorigenesis.

    Result of the chromosomal anomaly

    Hybrid gene
    Note Ectopic expression of an intact or truncated EVI1 transcript has been reported as a result of 3q26 rearrangements. Generally, 3q26 breakpoints map 3' to EVI1 in the inv(3) while the t(3;3) breakpoints more frequently reside 5' to EVI1. In addition expression of GR6/EVI1 and RPN1/EVI1 chimeras have been described in the t(3;3). Alternatively, AML1/MDS1, AML1/MDS1/EVI1 and AML1/EVI1 fusion transcripts are produced by the t(3;21)(q26;q22), while ETV6/MDS1/EVI1 and ETV6/EVI1 fusions are related to the t(3;12)(q26;p13). The net effect of these rearrangements comprises an EVI1 gain of function: as a result of EVI1 ectopic expression or resulting from MDS1/EVI1 inactivation by disruption of its PR domain.

    Several hybrid genes resulting from 3q26 rearrangements have been characterised and cloned, including the AML1/MDS1/EVI1 from the t(3;21)(q26;q22) and the ETV6/MDS1/EVI1 in the t(3;12)(q26;p13) these rearrangements are discussed elsewhere in the Atlas.

      

    Bibliography

    High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
    Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R, Slater R, Smit EM, Beverloo HB, Verhoef G, Verdonck LF, Ossenkoppele GJ, Sonneveld P, de Greef GE, Löwenberg B, Delwel R
    Blood. 2003 ; 101 (3) : 837-845.
    PMID 12393383
     
    Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML.
    Cuenco GM, Nucifora G, Ren R
    Proceedings of the National Academy of Sciences of the United States of America. 2000 ; 97 (4) : 1760-1765.
    PMID 10677531
     
    Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family.
    Fears S, Mathieu C, Zeleznik-Le N, Huang S, Rowley JD, Nucifora G
    Proceedings of the National Academy of Sciences of the United States of America. 1996 ; 93 (4) : 1642-1647.
    PMID 8643684
     
    The Evi1 proto-oncogene is required at midgestation for neural, heart, and paraxial mesenchyme development.
    Hoyt PR, Bartholomew C, Davis AJ, Yutzey K, Gamer LW, Potter SS, Ihle JN, Mucenski ML
    Mechanisms of development. 1997 ; 65 (1-2) : 55-70.
    PMID 9256345
     
    Molecular analysis of Evi1, a zinc finger oncogene involved in myeloid leukemia.
    Lopingco MC, Perkins AS
    Current topics in microbiology and immunology. 1996 ; 211 : 211-222.
    PMID 8585952
     
    Identification, nuclear localization, and DNA-binding activity of the zinc finger protein encoded by the Evi-1 myeloid transforming gene.
    Matsugi T, Morishita K, Ihle JN
    Molecular and cellular biology. 1990 ; 10 (3) : 1259-1264.
    PMID 2106070
     
    Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia.
    Mitani K, Ogawa S, Tanaka T, Miyoshi H, Kurokawa M, Mano H, Yazaki Y, Ohki M, Hirai H
    The EMBO journal. 1994 ; 13 (3) : 504-510.
    PMID 8313895
     
    Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26.
    Morishita K, Parganas E, William CL, Whittaker MH, Drabkin H, Oval J, Taetle R, Valentine MB, Ihle JN
    Proceedings of the National Academy of Sciences of the United States of America. 1992 ; 89 (9) : 3937-3941.
    PMID 1570317
     
    Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors.
    Mucenski ML, Taylor BA, Ihle JN, Hartley JW, Morse HC 3rd, Jenkins NA, Copeland NG
    Molecular and cellular biology. 1988 ; 8 (1) : 301-308.
    PMID 2827004
     
    The EVI1 gene in myeloid leukemia.
    Nucifora G
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1997 ; 11 (12) : 2022-2031.
    PMID 9447815
     
    Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders.
    Peeters P, Wlodarska I, Baens M, Criel A, Selleslag D, Hagemeijer A, Van den Berghe H, Marynen P
    Cancer research. 1997 ; 57 (4) : 564-569.
    PMID 9044825
     
    Activation of a novel gene in 3q21 and identification of intergenic fusion transcripts with ecotropic viral insertion site I in leukemia.
    Pekarsky Y, Rynditch A, Wieser R, Fonatsch C, Gardiner K
    Cancer research. 1997 ; 57 (18) : 3914-3919.
    PMID 9307271
     
    High resolution molecular cytogenetics and MDS1, MDS1/EVI1 and EVI1 expression patterns in rearrangements involving 3q26.
    Poppe B, Dastugue N, De Smet B, Yigit N, De Paepe A, Recher C, De Mas V, Hagemeijer A, Speleman F
    In preparation..
     
    Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations.
    Russell M, List A, Greenberg P, Woodward S, Glinsmann B, Parganas E, Ihle J, Taetle R
    Blood. 1994 ; 84 (4) : 1243-1248.
    PMID 8049440
     
    The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
    Soderholm J, Kobayashi H, Mathieu C, Rowley JD, Nucifora G
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1997 ; 11 (3) : 352-358.
    PMID 9067573
     
    Identification of a breakpoint cluster region 3' of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26).
    Suzukawa K, Parganas E, Gajjar A, Abe T, Takahashi S, Tani K, Asano S, Asou H, Kamada N, Yokota J
    Blood. 1994 ; 84 (8) : 2681-2688.
    PMID 7919381
     
    Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia.
    Vinatzer U, Mannhalter C, Mitterbauer M, Gruener H, Greinix H, Schmidt HH, Fonatsch C, Wieser R
    Genes, chromosomes & cancer. 2003 ; 36 (1) : 80-89.
    PMID 12461752
     

    Citation

    This paper should be referenced as such :
    Poppe, B ; Dastugue, N ; Speleman, F
    3q rearrangements in myeloid malignancies
    Atlas Genet Cytogenet Oncol Haematol. 2003;7(2):110-112.
    Free journal version : [ pdf ]   [ DOI ]
    On line version : http://AtlasGeneticsOncology.org/Anomalies/3qrearrmyeloID1125.html


    Other genes implicated (Data extracted from papers in the Atlas) [ 1 ]

    Genes PRDM16

    External links

    arrayMapTopo ( C42) Morph ( 9861/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
    arrayMapTopo ( C42) Morph ( 9975/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
    arrayMapTopo ( C42) Morph ( 9989/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
     
     
    Disease database3q26 rearrangements (MECOM) in myeloid malignancies
    REVIEW articlesautomatic search in PubMed
    Last year articlesautomatic search in PubMed
    All articlesautomatic search in PubMed


    © Atlas of Genetics and Cytogenetics in Oncology and Haematology
    indexed on : Fri Jun 30 11:22:01 CEST 2017


    Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

    For comments and suggestions or contributions, please contact us

    jlhuret@AtlasGeneticsOncology.org.